Commoney Wise
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
  • Login
  • Register

  Breaking
Dozens forced to evacuate from small cruise ship in Alaska after engine room fire June 6, 2023
Debt ceiling package does little to address America’s major fiscal problems June 6, 2023
Investors pull $790 million from crypto exchange Binance after SEC charges June 6, 2023
MBLY, EPAM, MKC and more June 6, 2023
DigiToads (TOADS) Rise to Prominence as Pepe (PEPE) & Dogecoin (DOGE) Craze Subsides June 6, 2023
Next
Prev

en English
en Englishes Españolde Deutschfr Françaisit Italianopt Portuguêsru Русскийzh-CN 简体中文hi हिन्दीja 日本語
Casino
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
No Result
View All Result
Commoney Wise
Casino
  • News
  • Politics
  • Business
  • Economy
  • Finance
  • Investing
  • Markets
  • Crypto
  • Tech
  • Videos
Home Business

Amgen close to deal to buy Horizon Therapeutics for $20bn

Staff by Staff
December 11, 2022
in Business
0 0
A A
0

Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets.

A deal between the California-based biotech and Horizon, which is headquartered in Ireland, would mark the largest pharmaceutical transaction since AstraZeneca bought Alexion for $39bn last year.

The takeover would give Amgen access to Horizon’s pipeline of drugs for rare autoimmune and inflammatory diseases, including its blockbuster treatment Tepezza.

Horizon said last month that it was in takeover talks with three potential suitors, among them Johnson & Johnson and Sanofi. The French drugmaker said on Sunday that it had evaluated the deal and decided that the price was not right.

The potential deal comes hot on the heels of Amgen’s $3.7bn acquisition of ChemoCentryx, a San Carlos, California-based company that develops drugs for inflammatory and autoimmune diseases as well as cancer.

Analysts have been predicting a boom in mergers and acquisitions in the pharmaceutical sector as valuations have come down in the worst biotech sell-off since the early 2000s. Shares in Horizon had fallen 27 per cent from the start of the year until late November, when the company confirmed it was engaged in preliminary deal discussions.

While there has been a broader slowdown in M&A this year, drugmakers have been busy putting their large piles of cash to work as they seek to replenish their drug pipelines.

Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals for $11.6bn. 

Still, 2022 has so far been a quieter year for M&A, with overall pharmaceutical and life sciences deal value down by 49 per cent year on year, and volumes falling by 28 per cent, according to data compiled by PwC.

Tim Walbert, Horizon’s chief executive, suffers from an autoimmune condition himself, and previously led the global development of Abbvie’s blockbuster Humira.

Horizon received regulatory approval for Tepezza in January 2020. In the third quarter, it had net sales for the drug of $490.9mn, guiding to a high teens percentage growth rate for the full year. In total, it forecasts net sales of between $3.59bn and $3.61bn, and adjusted earnings before interest, tax, depreciation and amortisation of $1.32bn to $1.34bn for 2022.

The company has an extensive pipeline of drugs targeting autoimmune diseases including rheumatoid arthritis, lupus, atopic dermatitis, and gout.

The deal was first reported by the Wall Street Journal.

Read the full article here

ShareTweetSharePinShareSendShare
https://www.madmoneycasino.com/?faff=667&sub=DemCasino

Related Articles

Business

David Zaslav turns to longtime confidante to steady wounded CNN

June 6, 2023
Business

Student loan refinance interest rates skyrocket for 5-year loans

June 6, 2023
Business

‘Prickly prince’ bets on a crude price rally

June 6, 2023
Business

JPMorgan CEO Jamie Dimon has ‘no plans’ to run for office, company says

June 6, 2023
Business

Prince Harry begins phone-hacking testimony against Mirror Group

June 6, 2023
Business

‘Great migration’ continues as more Americans flee to Florida, Texas

June 6, 2023
Load More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Commoney Wise

Commoney Wise is your one stop news website for the latest finance, business and crypto news, follow us to get the news that matters to your minute by minute.

Our Other Brands Kronosslott, Commoneywise, Demcasino.de, SportsExtremes.tv, Slotgamesusawwr, Coin Desk Times, Kingsofgolf.be

Topics

Business Commodities Crypto Economy Finance Forex Futures Investing Markets News Politics Stocks Tech Videos

Get Informed

The most important world news and events of the day

Be the first to know latest important news & events directly to your inbox.

By signing up, I agree to our TOS and Privacy Policy.

  • Privacy
  • Terms
  • Press
  • Advertise
  • Contact

© 2022 Commoney Wise. All Rights Reserved.

No Result
View All Result
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos

© 2022 Commoney Wise. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.